Caribou Biosciences reported early data suggesting its allogeneic, off‑the‑shelf CAR‑T candidate can induce deep remissions in B‑cell lymphoma. The preliminary results showed high overall and complete response rates with durable responses in a subset of patients, supporting the company’s strategy of manufacturing donor-derived cells matched to patients’ immune profiles. The findings, while early, revive investor and industry interest in off‑the‑shelf cell therapies that promise faster access and lower per-patient manufacturing time versus autologous CAR‑T. Caribou acknowledged further work and capital will be required to validate scalability and long-term safety compared with approved, patient-specific products.